Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in healthy volunteers
NCT07033455Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-1893 in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Maximum Plasma Concentration at 8 days, Time to Maximum Plasma Concentration at 8 days and 7 more. Started Jun 2025; status: completed.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07033455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033455.